Skip to main content
Fig. 2 | Molecular Cancer

Fig. 2

From: Harnessing the MYB-dependent TAL1 5’super-enhancer for targeted therapy in T-ALL

Fig. 2

Mebendazole delays tumor progression in 5’SE T-ALLs in vivo. A Schematic showing Mebendazole treatment settings. Adapted from “Mouse Experimental Timeline”, by BioRender.com (2022). Retrieved from https://app.biorender.com/biorender-templates. B Bioluminescence imaging of NSG recipient mice 31 days after injection with Jurkat cells. Representative images are shown. Mann–Whitney; Control vs. Preventive p = 0.03, Control vs. Curative p = 0.01. The Mean and SEM are shown. C hCD45 staining of bone marrow cells 28 days after injection with Jurkat luciferase expressing cells. Mann–Whitney; Control vs. Preventive p = 0.01, Control vs. Curative p = 0.02. The mean and SEM are shown. D Flow Cytometric peripheral blood staining of hCD45 21 days after injection with 5’SE PDX cells. Control vs. Preventive p = 0.03, Control vs. Curative p = 0.02. The mean and SEM are shown. E Kaplan Meier survival curves for Control, Preventive and Curative mice. Log-rank (Mantel-Cox) Test; Control vs. Preventive vs. Curative p = 0.007, Control vs. Preventive p = 0.005, Control vs. Curative p = 0.001. F Kaplan Meier survival curves for Control, Preventive and Curative 5’SE PDX mice. Log-rank (Mantel-Cox) Test; Control vs. Preventive vs. Curative p = 0.004, Control vs. Preventive p = 0.009, Control vs. Curative p = 0.01

Back to article page